Evaxion to Present New Preclinical Data for CMV Vaccine Candidate EVX-V1
EVAX sits 35% above its 52-week low of $2.258.
Summary
Evaxion announced it will present new preclinical data for its cytomegalovirus (CMV) vaccine candidate, EVX-V1, at an upcoming workshop, showcasing progress in a new pipeline area.
Key Events · Product Development and Regulatory · EVAX
-
Preclinical Data for CMV Vaccine
Evaxion will present new preclinical data for its cytomegalovirus (CMV) vaccine candidate, EVX-V1, at the International Herpesvirus Workshop on July 12, 2026.
-
AI-Immunology™ Platform Validation
The data will guide antigen selection for a broadly protective CMV vaccine, further validating the company's AI-Immunology™ platform in identifying novel antigens.
-
Addressing Unmet Medical Need
EVX-V1 targets CMV, a widespread infection with no approved vaccine, representing a significant unmet medical need and a potential market valued at $474.6 million in 2023.
Analysis · EVAX · Life Sciences
Evaxion's announcement of new preclinical data for its cytomegalovirus (CMV) vaccine candidate, EVX-V1, is an important step in its pipeline development. For a clinical-stage TechBio company, consistent progress in its drug candidates, especially in areas of high unmet medical need like CMV (a widespread infection with no approved vaccine), is crucial for demonstrating the value of its AI-Immunology™ platform and attracting future investment. This data will guide antigen selection, moving the program forward.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.7M. The 52-week trading range was $2.26 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.